Last 22,410
Change Today -520.00 / -2.27%
Volume 374.9K
As of 10:24 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical ind ltd (TEVA) Snapshot

Open
$22,880
Previous Close
$22,930
Day High
$22,920
Day Low
$22,410
52 Week High
12/7/14 - $23,070
52 Week Low
12/24/13 - $13,560
Market Cap
191.6B
Average Volume 10 Days
681.7K
EPS TTM
$3.23
Shares Outstanding
855.0M
EX-Date
11/17/14
P/E TM
17.7x
Dividend
$484.00
Dividend Yield
2.16%
Current Stock Chart for TEVA PHARMACEUTICAL IND LTD (TEVA)

teva pharmaceutical ind ltd (TEVA) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical ind ltd (TEVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical ind ltd (TEVA) Key Developments

Teva Pharmaceutical Industries Limited Announces FDA Approval of QNASL Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis

Teva Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) approved QNAS (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age. QNASL 40 mcg is a lower dose formulation of QNASL® Nasal Aerosol (80 mcg), a waterless (non-aqueous) intranasal corticosteroid (INS) spray currently available by prescription for adults and adolescents (12 years of age and older) for the treatment of nasal symptoms associated with AR. QNASL 40 mcg delivers effective symptom relief at one-fourth of the dosage approved to treat adults and is the first and only waterless hydrofluoroalkane (HFA) nasal allergy treatment to be approved for use in patients as young as four years of age. The drug is expected to become available by prescription in February 2015.

US Court Delays Teva Pharmaceutical Industries Launch of Generic Celebrex

The US Supreme Court of Appeal Court of Appeals has overturned the US Food and Drug Administration (FDA) decision allowing Teva Pharmaceutical Industries Ltd. to exclusively launch the first US Food and Drug Administration (FDA)-approved generic equivalent to Celebrex (Celecoxib) capsules in the US. Consequently, Teva will be compelled to wait until June 2015 before being allowed to launch the generic version of the arthritis, inflammation and chronic pain treatment, which earns Pfizer $3 billion annually. Moreover, the court ruling will allow Teva's rivals to launch generic versions of the treatment. Teva had announced that it would be immediately launching an exclusive version of generic Celebrex after becoming the first to receive FDA approval thus granting it 180 days generic exclusivity in the US. The court ruled that the patent for Celebrex had expired and that Teva was not entitled to the exclusivity.

Teva Pharmaceutical Industries Limited Provides Earnings Guidance for the Year Ending December 31, 2015

Teva Pharmaceutical Industries Limited provided earnings guidance for the year ending December 31, 2015. For the period, the company expects net revenues to be $19.0 billion to $19.4 billion, gross profit expects to be 59.5% to 61.5%, operating income expects to be $5.7 billion to $5.9 billion, finance expenses expects to be $250 million to $290 million, tax expects to be 19% to 21%, EPS expects to be $5.00 to $5.30, cash flow from operations expects to be $4.3 billion to $4.7 billion and free cash flow expects to be $3.5 billion to $3.7 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:IT 22,410.00 -520.00

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.97 USD -0.74
Actavis plc $261.66 USD -3.73
Baxter International Inc $74.70 USD +0.22
Eli Lilly & Co $71.42 USD -0.98
Valeant Pharmaceuticals International Inc C$167.77 CAD +2.31
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 18.0x
Price/Sales 2.4x
Price/Book 2.1x
Price/Cash Flow 20.2x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.